Avalo Therapeutics (NASDAQ:AVTX) Announces Quarterly Earnings Results

Avalo Therapeutics (NASDAQ:AVTX) announced its earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17, FiscalAI reports. The firm had revenue of $0.06 million for the quarter.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock traded up $0.83 during trading on Wednesday, hitting $14.28. The company’s stock had a trading volume of 416,890 shares, compared to its average volume of 521,977. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72. The stock has a market cap of $264.23 million, a price-to-earnings ratio of -2.51 and a beta of 0.84. The stock has a 50-day moving average price of $15.57 and a two-hundred day moving average price of $15.78.

Insider Transactions at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at $58,495.30. This trade represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.25% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors have recently made changes to their positions in AVTX. XTX Topco Ltd increased its stake in Avalo Therapeutics by 190.0% during the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after purchasing an additional 26,508 shares in the last quarter. Squadron Capital Management LLC bought a new position in shares of Avalo Therapeutics in the fourth quarter valued at $2,361,000. SummitTX Capital L.P. acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at about $3,557,000. Millennium Management LLC grew its holdings in shares of Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after buying an additional 522,548 shares during the last quarter. Finally, Caligan Partners LP increased its position in shares of Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on AVTX. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Guggenheim initiated coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a report on Tuesday. Finally, HC Wainwright upped their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.